Optimizerx CORP Form 4 insider transactions

Edward Stelmakh, CFO/COO of OptimizeRx Corp, files an amended SEC Form 4/A to correct an understatement of shares acquired and holdings following a restricted stock unit vesting.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, files an amendment to a previous Form 4 to correct an overstatement of shares withheld for tax obligations.

OptimizeRx CEO William Febbo was granted 60,000 restricted stock units on April 15, 2024, which will vest in three equal annual installments starting April 15, 2025.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the vesting and conversion of restricted stock units into common stock, along with a disposition of shares to cover tax obligations.